Review




Structured Review

Mutant Mouse Resource & Research Center d2cre b6 fvb cg tg drd2 cre er44gsat mmucd
Head-fixed mice learn to perform skilled forelimb movements to obtain a reward (A) Representation of injecting AAV9-hSyn-GRAB DA2h and AAV1-Syn-Flex-NES-jRGECO1a into M1. Coronal sections obtained from D1Cre and <t>D2Cre</t> mice showing expression of GRAB DA2h (green) and jRGECO1a (red) in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 500 μm. Magnification: 20×. See also for the histological map of GRAB DA2h and jRGECO1a expression and fiber tip placements. (B) Representation of the task in which head-fixed mice perform skilled forelimb movements with a joystick to obtain a delayed reward, and a fiber photometry setup for simultaneous recording of DA dynamics and population level Ca 2+ activity in the M1 forelimb area. See also for representative traces of neuronal Ca 2+ and DA signals acquired during training. (C) Increase in the number of rewarded joystick movements in D1Cre mice during training. (D) Movement kinematic parameters obtained from the early and late sessions in D1Cre mice showing that the average movement amplitude and velocity increased between training phases. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (E) Individual movement trajectories of an example D1Cre mouse aligned to the initial joystick position (black dot), and preferred movement direction in the group of D1Cre animals (based on all extracted trajectories). (F) Change in movement similarity in D1Cre mice (based on the average distance between pairwise trajectories). (Left to right) Similarity between the early and late sessions; similarity within the late session. (G–J) Same as (C)–(F) for D2Cre mice. In (C)–(J), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
D2cre B6 Fvb Cg Tg Drd2 Cre Er44gsat Mmucd, supplied by Mutant Mouse Resource & Research Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drd2/adora2a+b6+cg+cre+fvb+kg139gsat+mmucd+tg/pmc12969090-36-0-3
Average 86 stars, based on 1 article reviews
d2cre b6 fvb cg tg drd2 cre er44gsat mmucd - by Bioz Stars, 2026-10
86/100 stars

Images

1) Product Images from "The role of dopamine-sensitive motor cortical circuits in the development and execution of skilled forelimb movements"

Article Title: The role of dopamine-sensitive motor cortical circuits in the development and execution of skilled forelimb movements

Journal: iScience

doi: 10.1016/j.isci.2026.114983

Head-fixed mice learn to perform skilled forelimb movements to obtain a reward (A) Representation of injecting AAV9-hSyn-GRAB DA2h and AAV1-Syn-Flex-NES-jRGECO1a into M1. Coronal sections obtained from D1Cre and D2Cre mice showing expression of GRAB DA2h (green) and jRGECO1a (red) in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 500 μm. Magnification: 20×. See also for the histological map of GRAB DA2h and jRGECO1a expression and fiber tip placements. (B) Representation of the task in which head-fixed mice perform skilled forelimb movements with a joystick to obtain a delayed reward, and a fiber photometry setup for simultaneous recording of DA dynamics and population level Ca 2+ activity in the M1 forelimb area. See also for representative traces of neuronal Ca 2+ and DA signals acquired during training. (C) Increase in the number of rewarded joystick movements in D1Cre mice during training. (D) Movement kinematic parameters obtained from the early and late sessions in D1Cre mice showing that the average movement amplitude and velocity increased between training phases. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (E) Individual movement trajectories of an example D1Cre mouse aligned to the initial joystick position (black dot), and preferred movement direction in the group of D1Cre animals (based on all extracted trajectories). (F) Change in movement similarity in D1Cre mice (based on the average distance between pairwise trajectories). (Left to right) Similarity between the early and late sessions; similarity within the late session. (G–J) Same as (C)–(F) for D2Cre mice. In (C)–(J), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
Figure Legend Snippet: Head-fixed mice learn to perform skilled forelimb movements to obtain a reward (A) Representation of injecting AAV9-hSyn-GRAB DA2h and AAV1-Syn-Flex-NES-jRGECO1a into M1. Coronal sections obtained from D1Cre and D2Cre mice showing expression of GRAB DA2h (green) and jRGECO1a (red) in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 500 μm. Magnification: 20×. See also for the histological map of GRAB DA2h and jRGECO1a expression and fiber tip placements. (B) Representation of the task in which head-fixed mice perform skilled forelimb movements with a joystick to obtain a delayed reward, and a fiber photometry setup for simultaneous recording of DA dynamics and population level Ca 2+ activity in the M1 forelimb area. See also for representative traces of neuronal Ca 2+ and DA signals acquired during training. (C) Increase in the number of rewarded joystick movements in D1Cre mice during training. (D) Movement kinematic parameters obtained from the early and late sessions in D1Cre mice showing that the average movement amplitude and velocity increased between training phases. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (E) Individual movement trajectories of an example D1Cre mouse aligned to the initial joystick position (black dot), and preferred movement direction in the group of D1Cre animals (based on all extracted trajectories). (F) Change in movement similarity in D1Cre mice (based on the average distance between pairwise trajectories). (Left to right) Similarity between the early and late sessions; similarity within the late session. (G–J) Same as (C)–(F) for D2Cre mice. In (C)–(J), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

Techniques Used: Expressing, Activity Assay

DA dynamics in the M1 encode execution of skilled forelimb movement and reward consumption (A) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the baseline (BL) and between-session comparisons of movement- and reward-related periods (early vs. late). (B) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the BL and between-session comparisons of movement- and reward-related periods (early vs. late). (C) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the BL and between-session comparisons of movement- and reward-related periods (early vs. late). (D–F) Same as (A)–(C) for D2Cre mice. In (A)–(F), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Repeated-measure one-way ANOVA; multiple comparisons: BL mean vs. every other mean, movement (0–1 s) mean vs. reward (1–2 s) mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; or paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice and cross-correlations between DA and Ca 2+ signals.
Figure Legend Snippet: DA dynamics in the M1 encode execution of skilled forelimb movement and reward consumption (A) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the baseline (BL) and between-session comparisons of movement- and reward-related periods (early vs. late). (B) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the BL and between-session comparisons of movement- and reward-related periods (early vs. late). (C) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the BL and between-session comparisons of movement- and reward-related periods (early vs. late). (D–F) Same as (A)–(C) for D2Cre mice. In (A)–(F), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Repeated-measure one-way ANOVA; multiple comparisons: BL mean vs. every other mean, movement (0–1 s) mean vs. reward (1–2 s) mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; or paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice and cross-correlations between DA and Ca 2+ signals.

Techniques Used:

The neural response in the M1 reflects the movement vigor (A and B) Movement kinematic parameters obtained from the low- and high-amplitude trials during regular threshold session in D1Cre and D2Cre mice showing the difference in response vigor. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (C) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (D) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (E) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low and high amplitude trials (bottom). (F–H) Same as (C)–(E) for D2Cre mice. In (A)–(H), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice.
Figure Legend Snippet: The neural response in the M1 reflects the movement vigor (A and B) Movement kinematic parameters obtained from the low- and high-amplitude trials during regular threshold session in D1Cre and D2Cre mice showing the difference in response vigor. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (C) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (D) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (E) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low and high amplitude trials (bottom). (F–H) Same as (C)–(E) for D2Cre mice. In (A)–(H), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice.

Techniques Used:

The neural response in the M1 reflects the movement vigor during the increased threshold session (A and B) Movement kinematic parameters obtained from the low- and high-amplitude trials during the increased threshold session in D1Cre and D2Cre mice. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (C) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (D) Peri-event plots of the average normalized Ca 2+ signaling D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (E) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (F–H) Same as (C)–(E) for D2Cre mice. In (A)–(H) Data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-), and 12 D2Cre (10 Cre+ and 2 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice.
Figure Legend Snippet: The neural response in the M1 reflects the movement vigor during the increased threshold session (A and B) Movement kinematic parameters obtained from the low- and high-amplitude trials during the increased threshold session in D1Cre and D2Cre mice. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (C) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (D) Peri-event plots of the average normalized Ca 2+ signaling D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (E) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (F–H) Same as (C)–(E) for D2Cre mice. In (A)–(H) Data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-), and 12 D2Cre (10 Cre+ and 2 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice.

Techniques Used:

DA in the M1 signals actual reward availability during skilled performance (A) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the baseline (BL). (B) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the BL. (C) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the BL. (D–F) Same as (A)–(C) for D2Cre mice. In (A)–(F), data for “delayed reward” analysis were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals and for “omission” analysis from 9 D1Cre (7 Cre+ and 2 Cre-) and 8 D2Cre (8 Cre+) animals. Data are represented as mean ± SEM. Repeated-measure one-way ANOVA; multiple comparisons: BL mean vs. every other mean, movement (0–1 s) mean vs. expected reward (1–2 s) mean, expected reward (1–2 s) mean vs. actual reward (3–4 s) mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05 See also for comparisons between D1Cre and D2Cre mice.
Figure Legend Snippet: DA in the M1 signals actual reward availability during skilled performance (A) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the baseline (BL). (B) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the BL. (C) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the BL. (D–F) Same as (A)–(C) for D2Cre mice. In (A)–(F), data for “delayed reward” analysis were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals and for “omission” analysis from 9 D1Cre (7 Cre+ and 2 Cre-) and 8 D2Cre (8 Cre+) animals. Data are represented as mean ± SEM. Repeated-measure one-way ANOVA; multiple comparisons: BL mean vs. every other mean, movement (0–1 s) mean vs. expected reward (1–2 s) mean, expected reward (1–2 s) mean vs. actual reward (3–4 s) mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05 See also for comparisons between D1Cre and D2Cre mice.

Techniques Used:

A subset of D1+ and D2+ neurons of the M1 contacts long-range targets (A) Representation of the four major areas of rAAV2-Retro-EYFP and Fluoro-Green injections: primary motor cortex (M1), dorsolateral striatum (DLS), thalamus (Thal), and pontine nucleus (PN). See also for representative histology of the injection sites. (B and C) Coronal sections obtained from D1-tdTomato and D2Cre::Ai14 (tdTomato) mice showing laminar distribution of tdTomato (red) expressing D1+ or D2+ neurons and EYFP or FGr (green) expressing retrogradely labeled projection neurons in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 50 μm. See also for analysis of laminar distributions. (D) Cell density of D1+ neurons plotted as a function of distance from pia (where pia = 0 and white matter = 1; therefore, <0.5 indicates cells clustered in the upper layers, while >0.5 indicates cells clustered in the deep layers). (E) Colocalization of D1+ neurons with different populations of projection neurons. Percentage of D1+ neurons indicates colabeled cells across all layers that are also EYFP+ (% [D1+ EYFP+] / D1+) or FGr+ (% [D1+ FGr+] / D1+). Percentage of EYFP+ neurons indicates cells that are also D1+ (% [D1+ EYFP+] / EYFP+), and percentage of FGr+ neurons indicates cells that are D1+ (% [D1+ FGr+] / FGr+). (F) Comparison of labeling specificity of rAAV2-retro and FGr tracers measured by the number of cells labeled by each tracer. (G–I) Same as (D)–(F) for D2Cre mice. In (D)–(I), data were obtained from 21 D1-tdTomato and 19 D2Cre::Ai14 animals (2–3 mice per injection site, 4 slices per animal, slices were collected from −0.10 mm posterior to 1.00 mm anterior to the bregma). Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001. Two-way ANOVA; multiple comparisons: EYFP mean vs. FGr mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01. (B–I) cM1 (primary motor cortex injection, M1 forelimb area contralateral to the injection site); cDLS (DLS injection, M1 forelimb area contralateral to the injection site); iDLS (dorsolateral striatum injection, M1 forelimb area ipsilateral to the injection site); iThal (thalmus injection, M1 forelimb area ipsilateral to the injection site); iPN (pontine nucleus injection, M1 forelimb area ipsilateral to the injection site).
Figure Legend Snippet: A subset of D1+ and D2+ neurons of the M1 contacts long-range targets (A) Representation of the four major areas of rAAV2-Retro-EYFP and Fluoro-Green injections: primary motor cortex (M1), dorsolateral striatum (DLS), thalamus (Thal), and pontine nucleus (PN). See also for representative histology of the injection sites. (B and C) Coronal sections obtained from D1-tdTomato and D2Cre::Ai14 (tdTomato) mice showing laminar distribution of tdTomato (red) expressing D1+ or D2+ neurons and EYFP or FGr (green) expressing retrogradely labeled projection neurons in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 50 μm. See also for analysis of laminar distributions. (D) Cell density of D1+ neurons plotted as a function of distance from pia (where pia = 0 and white matter = 1; therefore, <0.5 indicates cells clustered in the upper layers, while >0.5 indicates cells clustered in the deep layers). (E) Colocalization of D1+ neurons with different populations of projection neurons. Percentage of D1+ neurons indicates colabeled cells across all layers that are also EYFP+ (% [D1+ EYFP+] / D1+) or FGr+ (% [D1+ FGr+] / D1+). Percentage of EYFP+ neurons indicates cells that are also D1+ (% [D1+ EYFP+] / EYFP+), and percentage of FGr+ neurons indicates cells that are D1+ (% [D1+ FGr+] / FGr+). (F) Comparison of labeling specificity of rAAV2-retro and FGr tracers measured by the number of cells labeled by each tracer. (G–I) Same as (D)–(F) for D2Cre mice. In (D)–(I), data were obtained from 21 D1-tdTomato and 19 D2Cre::Ai14 animals (2–3 mice per injection site, 4 slices per animal, slices were collected from −0.10 mm posterior to 1.00 mm anterior to the bregma). Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001. Two-way ANOVA; multiple comparisons: EYFP mean vs. FGr mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01. (B–I) cM1 (primary motor cortex injection, M1 forelimb area contralateral to the injection site); cDLS (DLS injection, M1 forelimb area contralateral to the injection site); iDLS (dorsolateral striatum injection, M1 forelimb area ipsilateral to the injection site); iThal (thalmus injection, M1 forelimb area ipsilateral to the injection site); iPN (pontine nucleus injection, M1 forelimb area ipsilateral to the injection site).

Techniques Used: Injection, Expressing, Labeling, Comparison

Related Articles

Polymerase Chain Reaction:

Article Title: TMEM145 is a principal component of outer hair cell stereocilia.
Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-TMEM145 polyclonal antibody Atlas Antibodies Cat# HPA060462; RRID:AB_2684285 TUB antibody Proteintech Cat# 17928-1-AP; RRID:AB_2212236 Anti-STRC polyclonal antibody Eurogentec N/A ARL13B antibody Proteintech Cat# 17711-1-AP; RRID:AB_2060867 Anti-KCNQ4 Antibody Alomone Labs Cat# APC-164; RRID:AB_2341042 Mouse Anti-Eps8 Monoclonal Antibody, Unconjugated, Clone 15 BD Biosciences Cat# 610144; RRID:AB_397545 Recombinant Anti-LHFPL5 antibody [EPR16285] - C-terminal Abcam Cat# ab192242; RRID:AB_2942040 Anti-CDH23 Antibody Prof. Ulrich Müller, John Hopkins University55 N/A DYKDDDDK tag antibody Proteintech Cat# 80801-2-RR; RRID: AB_3670488 V5-tag antibody Proteintech Cat# 81775-4-RR; RRID:AB_3670504 HA tag antibody Proteintech Cat# 51064-2-AP; RRID:AB_11042321 Goat Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor® 488 Conjugated Thermo Fisher Scientific Cat# A-11008; RRID:AB_143165 Goat Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor® 568 Conjugated Thermo Fisher Scientific Cat# A-11011; RRID:AB_143157 Goat Anti-Mouse IgG (H+L) Highly Crossadsorbed Antibody, Alexa Fluor® 647 Conjugated Thermo Fisher Scientific Cat# A-21236; RRID:AB_2535805 IRDye® 800CW Goat anti-Rabbit IgG LI-COR Biosciences Cat#926-32211; RRID: AB_621843 StarBright® Blue 700 Goat Anti-Mouse IgG Bio-Rad Cat# 12004159; RRID:AB_2884948 FluoTag®-X2 anti-ALFA AbberiorStar635P NanoTag Biotechnologies Cat# N1502-AB635P-L; RRID:AB_3075979 Bacterial and virus strains Subcloning EfficiencyTM DH5α Competent Cells Thermo Fisher Scientific Cat#18265017 Chemicals, peptides, and recombinant proteins Protease inhibitor cocktail Sigma-Aldrich Cat#P8349 PMSF solution Merck Cat#10837091001 Triton® X-100 ROTH Cat#3051.3 jetPRIME® Polyplus Cat#101000046 Polyethylenimine (PEI) Custom-made N/A LipofectamineTM 2000 Transfection Reagent Thermo Fisher Scientific Cat#11668030 FM1-43 dye solution MedChemExpress Cat#HY-D1434 GSK-A1 SYNkinase Cat#SYN-1219-M001 DAPI Nucleic Acid Stain Thermo Fisher Scientific Cat#D1306 Phalloidin-iFluor 633 Reagent Abcam Cat#ab176758 Phalloidin-iFluor 405 Reagent Abcam Cat#ab176752 1,2-Bis(2-Aminophenoxy)ethaneN,N,N′,N′-tetraacetic acid (BAPTA) Sigma-Aldrich Cat#A4926 Poly-D-lysine Thermo Fisher Scientific Cat#A3890401 Critical commercial assays SuperScript IV Reverse Transcriptase Thermo Fisher Scientific Cat#18090010 (Continued on next page) ll OPEN ACCESS Article e1 Neuron 114, 1–15.e1–e7, August 5, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER Mouse brain total extracted RNA Ambion N/A Phusion High-Fidelity DNA Polymerase Thermo Fisher Scientific Cat#F530S PfuUltra II Hotstart PCR Master Mix Agilent Cat#600852 EZviewTM Red ANTI-FLAG® M2 Affinity Gel Millipore Cat#F2426 Experimental models: Cell lines HEK293, Human Thermo Fisher Scientific Cat#11625019 HeLa, Human Prof. Ralf Jakob, Marburg56 N/A LLC-PK1-CL4, Pig James R. Bartles57 N/A Experimental models: Organisms/strains C57BL/6NCrl Charles River N/A C57BL/6NCrlTmem145em1(IMPC)Mbp/Mmucd MMRRC RRID:MMRRC_065589-UCD Tmem145mandolin/mandolin Potter et al.26 N/A STRC-KO Shubina-Oleinik et al.15 N/A Oligonucleotides See Table S1 N/A Recombinant DNA mTmem145-pEGFP-N1 This paper NM_183311.2 mTmem145ΔC-pEGFP-N1 This paper NM_183311.2 mTmem145-HA-pCDNA3.1(+) Genescript NM_183311.2 mTmem145-alfatag-pCDNA3.1(-) Genescript NM_183311.2 mTmem145-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mTmem145ΔGOLD-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mTmem145ΔC-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mSTRC-Myc-pCDNA3.1(+) This paper NM_021885.4; Subcloning from Shubina-Oleinik et al.15 TagBFP2-CAAX This paper N/A pcDNA3.1-MYO10-HMM-Nanotrap Bird et al.25 Addgene; Cat#87255 pEGFP-MYO10-HMM Bird et al.25 Addgene; Cat#87256 mTubby-DsREDmono-pEGFP-C1 Thallmair et al.42 NM_021885.4; mTubby-pRFP-C1 Thallmair et al.42 NM_021885.4; mTubby-V5-pCDNA3.1(+) Genescript NM_021885.4 Software and algorithms Graphpad Prism v5.0 GraphPad Software https://www.graphpad.com Igor Pro v8.0.4.2 Wavemetrics https://www.wavemetrics.com/ Fiji v2.14.0 Schneider et al.58 https://fiji.sc/ PYMOL v2.1.0 Schrodinger https://www.pymol.org/ Biorender Biorender https://www.biorender.com/ Adobe Illustrator v30.0 Adobe Inc. https://www.adobe.com/ Snapgene Dotmatics https://www.snapgene.com/ RStudio v4.4.0 Posit https://posit.co/ Superplot package Lord et al.59 N/A Interface Residues script SB Grid Consortium https://pymolwiki.org/InterfaceResidues NanoSPD ImageJ macro This paper DOI:10.5281/zenodo.18840150 Other AlphaFold Jumper et al.32 https://alphafoldserver.com ll OPEN ACCESSArticle Neuron 114, 1–15.e1–e7, August 5, 2026 e2 ..

Recombinant:

Article Title: TMEM145 is a principal component of outer hair cell stereocilia.
Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-TMEM145 polyclonal antibody Atlas Antibodies Cat# HPA060462; RRID:AB_2684285 TUB antibody Proteintech Cat# 17928-1-AP; RRID:AB_2212236 Anti-STRC polyclonal antibody Eurogentec N/A ARL13B antibody Proteintech Cat# 17711-1-AP; RRID:AB_2060867 Anti-KCNQ4 Antibody Alomone Labs Cat# APC-164; RRID:AB_2341042 Mouse Anti-Eps8 Monoclonal Antibody, Unconjugated, Clone 15 BD Biosciences Cat# 610144; RRID:AB_397545 Recombinant Anti-LHFPL5 antibody [EPR16285] - C-terminal Abcam Cat# ab192242; RRID:AB_2942040 Anti-CDH23 Antibody Prof. Ulrich Müller, John Hopkins University55 N/A DYKDDDDK tag antibody Proteintech Cat# 80801-2-RR; RRID: AB_3670488 V5-tag antibody Proteintech Cat# 81775-4-RR; RRID:AB_3670504 HA tag antibody Proteintech Cat# 51064-2-AP; RRID:AB_11042321 Goat Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor® 488 Conjugated Thermo Fisher Scientific Cat# A-11008; RRID:AB_143165 Goat Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor® 568 Conjugated Thermo Fisher Scientific Cat# A-11011; RRID:AB_143157 Goat Anti-Mouse IgG (H+L) Highly Crossadsorbed Antibody, Alexa Fluor® 647 Conjugated Thermo Fisher Scientific Cat# A-21236; RRID:AB_2535805 IRDye® 800CW Goat anti-Rabbit IgG LI-COR Biosciences Cat#926-32211; RRID: AB_621843 StarBright® Blue 700 Goat Anti-Mouse IgG Bio-Rad Cat# 12004159; RRID:AB_2884948 FluoTag®-X2 anti-ALFA AbberiorStar635P NanoTag Biotechnologies Cat# N1502-AB635P-L; RRID:AB_3075979 Bacterial and virus strains Subcloning EfficiencyTM DH5α Competent Cells Thermo Fisher Scientific Cat#18265017 Chemicals, peptides, and recombinant proteins Protease inhibitor cocktail Sigma-Aldrich Cat#P8349 PMSF solution Merck Cat#10837091001 Triton® X-100 ROTH Cat#3051.3 jetPRIME® Polyplus Cat#101000046 Polyethylenimine (PEI) Custom-made N/A LipofectamineTM 2000 Transfection Reagent Thermo Fisher Scientific Cat#11668030 FM1-43 dye solution MedChemExpress Cat#HY-D1434 GSK-A1 SYNkinase Cat#SYN-1219-M001 DAPI Nucleic Acid Stain Thermo Fisher Scientific Cat#D1306 Phalloidin-iFluor 633 Reagent Abcam Cat#ab176758 Phalloidin-iFluor 405 Reagent Abcam Cat#ab176752 1,2-Bis(2-Aminophenoxy)ethaneN,N,N′,N′-tetraacetic acid (BAPTA) Sigma-Aldrich Cat#A4926 Poly-D-lysine Thermo Fisher Scientific Cat#A3890401 Critical commercial assays SuperScript IV Reverse Transcriptase Thermo Fisher Scientific Cat#18090010 (Continued on next page) ll OPEN ACCESS Article e1 Neuron 114, 1–15.e1–e7, August 5, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER Mouse brain total extracted RNA Ambion N/A Phusion High-Fidelity DNA Polymerase Thermo Fisher Scientific Cat#F530S PfuUltra II Hotstart PCR Master Mix Agilent Cat#600852 EZviewTM Red ANTI-FLAG® M2 Affinity Gel Millipore Cat#F2426 Experimental models: Cell lines HEK293, Human Thermo Fisher Scientific Cat#11625019 HeLa, Human Prof. Ralf Jakob, Marburg56 N/A LLC-PK1-CL4, Pig James R. Bartles57 N/A Experimental models: Organisms/strains C57BL/6NCrl Charles River N/A C57BL/6NCrlTmem145em1(IMPC)Mbp/Mmucd MMRRC RRID:MMRRC_065589-UCD Tmem145mandolin/mandolin Potter et al.26 N/A STRC-KO Shubina-Oleinik et al.15 N/A Oligonucleotides See Table S1 N/A Recombinant DNA mTmem145-pEGFP-N1 This paper NM_183311.2 mTmem145ΔC-pEGFP-N1 This paper NM_183311.2 mTmem145-HA-pCDNA3.1(+) Genescript NM_183311.2 mTmem145-alfatag-pCDNA3.1(-) Genescript NM_183311.2 mTmem145-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mTmem145ΔGOLD-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mTmem145ΔC-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mSTRC-Myc-pCDNA3.1(+) This paper NM_021885.4; Subcloning from Shubina-Oleinik et al.15 TagBFP2-CAAX This paper N/A pcDNA3.1-MYO10-HMM-Nanotrap Bird et al.25 Addgene; Cat#87255 pEGFP-MYO10-HMM Bird et al.25 Addgene; Cat#87256 mTubby-DsREDmono-pEGFP-C1 Thallmair et al.42 NM_021885.4; mTubby-pRFP-C1 Thallmair et al.42 NM_021885.4; mTubby-V5-pCDNA3.1(+) Genescript NM_021885.4 Software and algorithms Graphpad Prism v5.0 GraphPad Software https://www.graphpad.com Igor Pro v8.0.4.2 Wavemetrics https://www.wavemetrics.com/ Fiji v2.14.0 Schneider et al.58 https://fiji.sc/ PYMOL v2.1.0 Schrodinger https://www.pymol.org/ Biorender Biorender https://www.biorender.com/ Adobe Illustrator v30.0 Adobe Inc. https://www.adobe.com/ Snapgene Dotmatics https://www.snapgene.com/ RStudio v4.4.0 Posit https://posit.co/ Superplot package Lord et al.59 N/A Interface Residues script SB Grid Consortium https://pymolwiki.org/InterfaceResidues NanoSPD ImageJ macro This paper DOI:10.5281/zenodo.18840150 Other AlphaFold Jumper et al.32 https://alphafoldserver.com ll OPEN ACCESSArticle Neuron 114, 1–15.e1–e7, August 5, 2026 e2 ..

Subcloning:

Article Title: TMEM145 is a principal component of outer hair cell stereocilia.
Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-TMEM145 polyclonal antibody Atlas Antibodies Cat# HPA060462; RRID:AB_2684285 TUB antibody Proteintech Cat# 17928-1-AP; RRID:AB_2212236 Anti-STRC polyclonal antibody Eurogentec N/A ARL13B antibody Proteintech Cat# 17711-1-AP; RRID:AB_2060867 Anti-KCNQ4 Antibody Alomone Labs Cat# APC-164; RRID:AB_2341042 Mouse Anti-Eps8 Monoclonal Antibody, Unconjugated, Clone 15 BD Biosciences Cat# 610144; RRID:AB_397545 Recombinant Anti-LHFPL5 antibody [EPR16285] - C-terminal Abcam Cat# ab192242; RRID:AB_2942040 Anti-CDH23 Antibody Prof. Ulrich Müller, John Hopkins University55 N/A DYKDDDDK tag antibody Proteintech Cat# 80801-2-RR; RRID: AB_3670488 V5-tag antibody Proteintech Cat# 81775-4-RR; RRID:AB_3670504 HA tag antibody Proteintech Cat# 51064-2-AP; RRID:AB_11042321 Goat Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor® 488 Conjugated Thermo Fisher Scientific Cat# A-11008; RRID:AB_143165 Goat Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor® 568 Conjugated Thermo Fisher Scientific Cat# A-11011; RRID:AB_143157 Goat Anti-Mouse IgG (H+L) Highly Crossadsorbed Antibody, Alexa Fluor® 647 Conjugated Thermo Fisher Scientific Cat# A-21236; RRID:AB_2535805 IRDye® 800CW Goat anti-Rabbit IgG LI-COR Biosciences Cat#926-32211; RRID: AB_621843 StarBright® Blue 700 Goat Anti-Mouse IgG Bio-Rad Cat# 12004159; RRID:AB_2884948 FluoTag®-X2 anti-ALFA AbberiorStar635P NanoTag Biotechnologies Cat# N1502-AB635P-L; RRID:AB_3075979 Bacterial and virus strains Subcloning EfficiencyTM DH5α Competent Cells Thermo Fisher Scientific Cat#18265017 Chemicals, peptides, and recombinant proteins Protease inhibitor cocktail Sigma-Aldrich Cat#P8349 PMSF solution Merck Cat#10837091001 Triton® X-100 ROTH Cat#3051.3 jetPRIME® Polyplus Cat#101000046 Polyethylenimine (PEI) Custom-made N/A LipofectamineTM 2000 Transfection Reagent Thermo Fisher Scientific Cat#11668030 FM1-43 dye solution MedChemExpress Cat#HY-D1434 GSK-A1 SYNkinase Cat#SYN-1219-M001 DAPI Nucleic Acid Stain Thermo Fisher Scientific Cat#D1306 Phalloidin-iFluor 633 Reagent Abcam Cat#ab176758 Phalloidin-iFluor 405 Reagent Abcam Cat#ab176752 1,2-Bis(2-Aminophenoxy)ethaneN,N,N′,N′-tetraacetic acid (BAPTA) Sigma-Aldrich Cat#A4926 Poly-D-lysine Thermo Fisher Scientific Cat#A3890401 Critical commercial assays SuperScript IV Reverse Transcriptase Thermo Fisher Scientific Cat#18090010 (Continued on next page) ll OPEN ACCESS Article e1 Neuron 114, 1–15.e1–e7, August 5, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER Mouse brain total extracted RNA Ambion N/A Phusion High-Fidelity DNA Polymerase Thermo Fisher Scientific Cat#F530S PfuUltra II Hotstart PCR Master Mix Agilent Cat#600852 EZviewTM Red ANTI-FLAG® M2 Affinity Gel Millipore Cat#F2426 Experimental models: Cell lines HEK293, Human Thermo Fisher Scientific Cat#11625019 HeLa, Human Prof. Ralf Jakob, Marburg56 N/A LLC-PK1-CL4, Pig James R. Bartles57 N/A Experimental models: Organisms/strains C57BL/6NCrl Charles River N/A C57BL/6NCrlTmem145em1(IMPC)Mbp/Mmucd MMRRC RRID:MMRRC_065589-UCD Tmem145mandolin/mandolin Potter et al.26 N/A STRC-KO Shubina-Oleinik et al.15 N/A Oligonucleotides See Table S1 N/A Recombinant DNA mTmem145-pEGFP-N1 This paper NM_183311.2 mTmem145ΔC-pEGFP-N1 This paper NM_183311.2 mTmem145-HA-pCDNA3.1(+) Genescript NM_183311.2 mTmem145-alfatag-pCDNA3.1(-) Genescript NM_183311.2 mTmem145-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mTmem145ΔGOLD-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mTmem145ΔC-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mSTRC-Myc-pCDNA3.1(+) This paper NM_021885.4; Subcloning from Shubina-Oleinik et al.15 TagBFP2-CAAX This paper N/A pcDNA3.1-MYO10-HMM-Nanotrap Bird et al.25 Addgene; Cat#87255 pEGFP-MYO10-HMM Bird et al.25 Addgene; Cat#87256 mTubby-DsREDmono-pEGFP-C1 Thallmair et al.42 NM_021885.4; mTubby-pRFP-C1 Thallmair et al.42 NM_021885.4; mTubby-V5-pCDNA3.1(+) Genescript NM_021885.4 Software and algorithms Graphpad Prism v5.0 GraphPad Software https://www.graphpad.com Igor Pro v8.0.4.2 Wavemetrics https://www.wavemetrics.com/ Fiji v2.14.0 Schneider et al.58 https://fiji.sc/ PYMOL v2.1.0 Schrodinger https://www.pymol.org/ Biorender Biorender https://www.biorender.com/ Adobe Illustrator v30.0 Adobe Inc. https://www.adobe.com/ Snapgene Dotmatics https://www.snapgene.com/ RStudio v4.4.0 Posit https://posit.co/ Superplot package Lord et al.59 N/A Interface Residues script SB Grid Consortium https://pymolwiki.org/InterfaceResidues NanoSPD ImageJ macro This paper DOI:10.5281/zenodo.18840150 Other AlphaFold Jumper et al.32 https://alphafoldserver.com ll OPEN ACCESSArticle Neuron 114, 1–15.e1–e7, August 5, 2026 e2 ..

Software:

Article Title: TMEM145 is a principal component of outer hair cell stereocilia.
Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-TMEM145 polyclonal antibody Atlas Antibodies Cat# HPA060462; RRID:AB_2684285 TUB antibody Proteintech Cat# 17928-1-AP; RRID:AB_2212236 Anti-STRC polyclonal antibody Eurogentec N/A ARL13B antibody Proteintech Cat# 17711-1-AP; RRID:AB_2060867 Anti-KCNQ4 Antibody Alomone Labs Cat# APC-164; RRID:AB_2341042 Mouse Anti-Eps8 Monoclonal Antibody, Unconjugated, Clone 15 BD Biosciences Cat# 610144; RRID:AB_397545 Recombinant Anti-LHFPL5 antibody [EPR16285] - C-terminal Abcam Cat# ab192242; RRID:AB_2942040 Anti-CDH23 Antibody Prof. Ulrich Müller, John Hopkins University55 N/A DYKDDDDK tag antibody Proteintech Cat# 80801-2-RR; RRID: AB_3670488 V5-tag antibody Proteintech Cat# 81775-4-RR; RRID:AB_3670504 HA tag antibody Proteintech Cat# 51064-2-AP; RRID:AB_11042321 Goat Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor® 488 Conjugated Thermo Fisher Scientific Cat# A-11008; RRID:AB_143165 Goat Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor® 568 Conjugated Thermo Fisher Scientific Cat# A-11011; RRID:AB_143157 Goat Anti-Mouse IgG (H+L) Highly Crossadsorbed Antibody, Alexa Fluor® 647 Conjugated Thermo Fisher Scientific Cat# A-21236; RRID:AB_2535805 IRDye® 800CW Goat anti-Rabbit IgG LI-COR Biosciences Cat#926-32211; RRID: AB_621843 StarBright® Blue 700 Goat Anti-Mouse IgG Bio-Rad Cat# 12004159; RRID:AB_2884948 FluoTag®-X2 anti-ALFA AbberiorStar635P NanoTag Biotechnologies Cat# N1502-AB635P-L; RRID:AB_3075979 Bacterial and virus strains Subcloning EfficiencyTM DH5α Competent Cells Thermo Fisher Scientific Cat#18265017 Chemicals, peptides, and recombinant proteins Protease inhibitor cocktail Sigma-Aldrich Cat#P8349 PMSF solution Merck Cat#10837091001 Triton® X-100 ROTH Cat#3051.3 jetPRIME® Polyplus Cat#101000046 Polyethylenimine (PEI) Custom-made N/A LipofectamineTM 2000 Transfection Reagent Thermo Fisher Scientific Cat#11668030 FM1-43 dye solution MedChemExpress Cat#HY-D1434 GSK-A1 SYNkinase Cat#SYN-1219-M001 DAPI Nucleic Acid Stain Thermo Fisher Scientific Cat#D1306 Phalloidin-iFluor 633 Reagent Abcam Cat#ab176758 Phalloidin-iFluor 405 Reagent Abcam Cat#ab176752 1,2-Bis(2-Aminophenoxy)ethaneN,N,N′,N′-tetraacetic acid (BAPTA) Sigma-Aldrich Cat#A4926 Poly-D-lysine Thermo Fisher Scientific Cat#A3890401 Critical commercial assays SuperScript IV Reverse Transcriptase Thermo Fisher Scientific Cat#18090010 (Continued on next page) ll OPEN ACCESS Article e1 Neuron 114, 1–15.e1–e7, August 5, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER Mouse brain total extracted RNA Ambion N/A Phusion High-Fidelity DNA Polymerase Thermo Fisher Scientific Cat#F530S PfuUltra II Hotstart PCR Master Mix Agilent Cat#600852 EZviewTM Red ANTI-FLAG® M2 Affinity Gel Millipore Cat#F2426 Experimental models: Cell lines HEK293, Human Thermo Fisher Scientific Cat#11625019 HeLa, Human Prof. Ralf Jakob, Marburg56 N/A LLC-PK1-CL4, Pig James R. Bartles57 N/A Experimental models: Organisms/strains C57BL/6NCrl Charles River N/A C57BL/6NCrlTmem145em1(IMPC)Mbp/Mmucd MMRRC RRID:MMRRC_065589-UCD Tmem145mandolin/mandolin Potter et al.26 N/A STRC-KO Shubina-Oleinik et al.15 N/A Oligonucleotides See Table S1 N/A Recombinant DNA mTmem145-pEGFP-N1 This paper NM_183311.2 mTmem145ΔC-pEGFP-N1 This paper NM_183311.2 mTmem145-HA-pCDNA3.1(+) Genescript NM_183311.2 mTmem145-alfatag-pCDNA3.1(-) Genescript NM_183311.2 mTmem145-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mTmem145ΔGOLD-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mTmem145ΔC-3xFLAG-pCDNA3.1(+) This paper NM_183311.2 mSTRC-Myc-pCDNA3.1(+) This paper NM_021885.4; Subcloning from Shubina-Oleinik et al.15 TagBFP2-CAAX This paper N/A pcDNA3.1-MYO10-HMM-Nanotrap Bird et al.25 Addgene; Cat#87255 pEGFP-MYO10-HMM Bird et al.25 Addgene; Cat#87256 mTubby-DsREDmono-pEGFP-C1 Thallmair et al.42 NM_021885.4; mTubby-pRFP-C1 Thallmair et al.42 NM_021885.4; mTubby-V5-pCDNA3.1(+) Genescript NM_021885.4 Software and algorithms Graphpad Prism v5.0 GraphPad Software https://www.graphpad.com Igor Pro v8.0.4.2 Wavemetrics https://www.wavemetrics.com/ Fiji v2.14.0 Schneider et al.58 https://fiji.sc/ PYMOL v2.1.0 Schrodinger https://www.pymol.org/ Biorender Biorender https://www.biorender.com/ Adobe Illustrator v30.0 Adobe Inc. https://www.adobe.com/ Snapgene Dotmatics https://www.snapgene.com/ RStudio v4.4.0 Posit https://posit.co/ Superplot package Lord et al.59 N/A Interface Residues script SB Grid Consortium https://pymolwiki.org/InterfaceResidues NanoSPD ImageJ macro This paper DOI:10.5281/zenodo.18840150 Other AlphaFold Jumper et al.32 https://alphafoldserver.com ll OPEN ACCESSArticle Neuron 114, 1–15.e1–e7, August 5, 2026 e2 ..

Transgenic Assay:

Article Title: Neuronal HDAC9: A key regulator of cognitive and synaptic aging, rescuing Alzheimer's disease-related phenotypes.
Article Snippet: .. The 5xFAD and APP/PS1 transgenic mice were obtained from Mutant Mouse Resource & Research Centers (MMRRC). ..

Mutagenesis:

Article Title: Neuronal HDAC9: A key regulator of cognitive and synaptic aging, rescuing Alzheimer's disease-related phenotypes.
Article Snippet: .. The 5xFAD and APP/PS1 transgenic mice were obtained from Mutant Mouse Resource & Research Centers (MMRRC). ..

Article Title: Transcriptomic and Proteomic Analyses Show Minimal Role for ST2 on MCPT5-Expressing Mast Cells in Primary Heligmosomoides polygyrus bakeri Infection.
Article Snippet: .. C57BL/6N- Atm1Brd Il1rl1tm1c(KOMP)Wtsi/RleeMmucd mice, RRID:MMRRC_048182UCD (known henceforth as ‘ST2f/f’), were obtained from the Mutant Mouse Resource and Research Center (MMRRC) at University of California at Davis, an NIH- funded strain repository, and were donated to the MMRRC by The KOMP Repository, University of California, Davis; originating from Dr. Richard Lee, Brigham and Women's Hospital [17]. ..

Article Title: Distinct laminar origins of sensory-evoked high-gamma and low-frequency ECoG signals revealed by optogenetics
Article Snippet: .. WT and Drd3 [(Tg(Drd3-cre) KI196Gsat/Gene Expression in the Nervous System Atlas (GENSAT) project through the Mutant Mouse Regional Resource Centers (MMRRC) (strain number 034610) JAX #)] (Gensat MMRRC, strain number 034610) mice were C57Bl6 background while Rbp4 [(Tg(Rbp4-cre) KL100Gsat/(GENSAT line # KL100)] were on Agouti/C57Bl6 mixed background. ..

Article Title: Role of Complement Component 9 in Bone Health: Causal Evidence in Humans and Mechanistic Studies in Mice.
Article Snippet: The mice were housed together in a standard animal facility under controlled temperature (22 °C) and photo periods (12 h of light, 12 h of darkness) with free access to water and food pellets (Teklad diet 2016, Envigo, Indianapolis, IN, USA). .. The mouse strain used for this research project, C57BL/6NC9tm1.1(KOMP)Vlcg/JMmucd, RRID:MMRRC_046855UCD, was obtained from the Mutant Mouse Resource and Research Center (MMRRC) at University of California at Davis, an NIH-funded strain repository, and was donated to the MMRRC by The KOMP Repository, University of California, Davis; Originating from Stephen Murray, The Jackson Laboratory [17]. .. Heterozygous C57BL/6N-C9tm1.1(KOMP)Vlcg/JMmucd female mice (C9+/−) were crossed with WT male mice purchased from Taconic (C57BL/6NTac).

Article Title: Role of Complement Component 9 in Bone Health: Causal Evidence in Humans and Mechanistic Studies in Mice
Article Snippet: The mice were housed together in a standard animal facility under controlled temperature (22 °C) and photo periods (12 h of light, 12 h of darkness) with free access to water and food pellets (Teklad diet 2016, Envigo, Indianapolis, IN, USA). .. The mouse strain used for this research project, C57BL/6N-C9 tm1.1(KOMP)Vlcg /JMmucd, RRID:MMRRC_046855-UCD, was obtained from the Mutant Mouse Resource and Research Center (MMRRC) at University of California at Davis, an NIH-funded strain repository, and was donated to the MMRRC by The KOMP Repository, University of California, Davis; Originating from Stephen Murray, The Jackson Laboratory [ ]. .. Heterozygous C57BL/6N-C9 tm1.1(KOMP)Vlcg /JMmucd female mice ( C9 +/− ) were crossed with WT male mice purchased from Taconic (C57BL/6NTac).

Article Title: TMEM145 is a principal component of outer hair cell stereocilia.
Article Snippet: C57BL/6NCrl mice derived from Charles River were considered as WT mice and all mice strains that have been used in the experiments were crossed within a C57BL/6NCrl genetic background. .. The mouse strain used for this research project, C57BL/6NCrl-Tmem145em1(IMPC)Mbp/Mmucd, RRID:MMRRC_065589-UCD, was obtained from the Mutant Mouse Resource and Research Center (MMRRC) at University of California at Davis, an NIH-funded strain repository, and was donated to the MMRRC by Kent Lloyd, D.V.M., University of California, Davis. ..

Expressing:

Article Title: Distinct laminar origins of sensory-evoked high-gamma and low-frequency ECoG signals revealed by optogenetics
Article Snippet: .. WT and Drd3 [(Tg(Drd3-cre) KI196Gsat/Gene Expression in the Nervous System Atlas (GENSAT) project through the Mutant Mouse Regional Resource Centers (MMRRC) (strain number 034610) JAX #)] (Gensat MMRRC, strain number 034610) mice were C57Bl6 background while Rbp4 [(Tg(Rbp4-cre) KL100Gsat/(GENSAT line # KL100)] were on Agouti/C57Bl6 mixed background. ..

other:

Article Title: Cocaine-Induced Immediate-Early Gene Expression in the Nucleus Accumbens: Roles of Separate cAMP Sensors.
Article Snippet: Immediateearly gene (IEG) induction guides elucidation of signaling pathways mediating neuronal plasticity underlying compulsive use of psychostimulants.. IEG induction after psychostimulant administration has been attributed to both PKAand RapGEF2dependent signaling pathways initiated by D1 receptor stimulation by dopamine.. However, it is not clear how each pathway contributes individually to IEG induction, dopaminoceptive neuronal activity, and neuronal plasticity.



Similar Products

94
MedChemExpress gαi coupled receptors
(A, B). Single-cell dose-response curves for (A) Gαs-coupled DRD1 and <t>(B)</t> <t>Gαi-coupled</t> <t>DRD2</t> in CHO-K1::cAMPinG1 cells transiently expressing HALO-tagged receptors. DRD2 was stimulated in the presence of 10 µM forskolin to elevate the baseline cAMP level. Cells are binned and colored by their measured surface receptor abundance (arbitrary flow-cytometry units; see color bars). Solid lines represent joint fits of the operational model (R 2 = 0.98 for DRD1; R 2 = 0.97 for DRD2) with binding affinity (Kd) locked to established IUPHAR values (fit values and 95% CIs are provided in ). Data represent per-bin medians, with error bars indicating ±1 SEM across independent replicate dates (n = 4 for DRD1, n = 5 for DRD2). The remaining subtypes <t>(DRD3,</t> <t>DRD4,</t> DRD5) are characterized in Fig. S3. (C, D) DRD1 dopamine dose-response under siRNA knockdown of Gαs at (C) 1 nM and (D) 33 nM siGNAS (ΔGs), overlaid on the wild-type Gαs response, binned by surface DRD1 abundance (colors as in A). Solid lines are the shared-parameter operational-model fit in which only the available transducer pool [Gs] varies per condition ; Gαs depletion right-shifts the curves along the dose axis without lowering the maximal response. (E). Schematic of the modified operational model. Ligand binding ([L]) yields a fractional receptor occupancy (ρ). This fraction is multiplied by the measured surface receptor abundance ([R]) to yield a composite signaling drive (D = [R] · [G] · ρ). The drive is processed through a saturable Hill-type transducer function (S) to compute the final integrated cAMP output (y). Full mathematical derivation is provided in the Supplementary Information. (F). Master-curve collapse across receptor abundances. Plotting the normalized transducer output (S) against the composite signaling drive (D) collapses the variable dose-response families onto a single, invariant master curve for each receptor subtype. This confirms that cellular cAMP responses are governed by the combined drive quantity rather than receptor density or ligand concentration independently.
Gαi Coupled Receptors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drd2/DRD2%2C+Human/bio_rxiv__64898__2026__07__10__737756-257-3-16
Average 94 stars, based on 1 article reviews
gαi coupled receptors - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

95
Thermo Fisher gene exp drd2 rn00561126 m1
Sympathoadrenal response and dopaminergic action with agonist bromocriptine (A–C) Recurrent BROMO administration in i.c.v. reduced food intake and BG response. (A) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) for 3 days into i.c.v. (B) BG on day 4 following singular injection of INS (15 U/kg NPH) Groups were compared via two-way ANOVA. (C) Cumulative food intake after INS injection (∗ p < 0.005 RBROMO i.c.v. vs. RCSF i.c.v. + INS). Groups were compared via unpaired t test. Each bar represents the mean + SEM. (D–H) Recurrent BROMO administration in i.c.v. and effects on CRR. (D) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) into i.c.v.. (E) BG during hyperinsulinemic-hypoglycemic clamp where BG is held at 40–45 mg/dL for 90 min. Groups were compared via two-way ANOVA. (F) Ginf. Rate during clamp (∗∗∗∗ p < 0.0001 vs. RBROMO). Groups were compared via unpaired t test. (G) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (H) Peak glucagon concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. Each bar represents the mean + SEM. (I) Dopaminergic gene expression in VTA. Relative gene product expression of COMT, DDC, <t>DRD2,</t> SLC6A3 in the ventral tegmental area following 3-day treatment with RS ( n = 6), RH ( n = 7), or RH + MET ( n = 6) (∗ p < 0.04 RS vs. RH + MET; # p < 0.04 RH vs. RH + MET). Groups were compared via one-way ANOVA. Each bar represents the mean + SEM. (J–O) Recurrent BROMO infusion in VTA effects on CRR. (J) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO (n = 7–9, 5 μg/day; infusion rate 0.1 μL/min). (K) BG concentration during hyperinsulinemic-hypoglycemic clamp, which held BG at 40–50 mg/dL for 90 min. Groups were compared via two-way ANOVA. (L) Ginf. rate during clamp (∗∗∗∗ p < 0.001 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (M) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.05 BROMO vs. SAL). Groups were analyzed via unpaired t test. (N) Relative gene expression of DRD2 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA (∗ p < 0.05 aCSF vs. BROMO). Groups were compared via unpaired t test. (O) Relative gene expression of SLC6A3 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA ( p = 0.21). Groups were compared via unpaired t test. Each bar represents the mean + SEM.
Gene Exp Drd2 Rn00561126 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drd2/Gene+Exp%2E+Drd2%2C+Rn00561126_m1/pmc13130643-425-42-31
Average 95 stars, based on 1 article reviews
gene exp drd2 rn00561126 m1 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

99
Thermo Fisher gene exp drd2 hs00241436 m1
Sympathoadrenal response and dopaminergic action with agonist bromocriptine (A–C) Recurrent BROMO administration in i.c.v. reduced food intake and BG response. (A) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) for 3 days into i.c.v. (B) BG on day 4 following singular injection of INS (15 U/kg NPH) Groups were compared via two-way ANOVA. (C) Cumulative food intake after INS injection (∗ p < 0.005 RBROMO i.c.v. vs. RCSF i.c.v. + INS). Groups were compared via unpaired t test. Each bar represents the mean + SEM. (D–H) Recurrent BROMO administration in i.c.v. and effects on CRR. (D) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) into i.c.v.. (E) BG during hyperinsulinemic-hypoglycemic clamp where BG is held at 40–45 mg/dL for 90 min. Groups were compared via two-way ANOVA. (F) Ginf. Rate during clamp (∗∗∗∗ p < 0.0001 vs. RBROMO). Groups were compared via unpaired t test. (G) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (H) Peak glucagon concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. Each bar represents the mean + SEM. (I) Dopaminergic gene expression in VTA. Relative gene product expression of COMT, DDC, <t>DRD2,</t> SLC6A3 in the ventral tegmental area following 3-day treatment with RS ( n = 6), RH ( n = 7), or RH + MET ( n = 6) (∗ p < 0.04 RS vs. RH + MET; # p < 0.04 RH vs. RH + MET). Groups were compared via one-way ANOVA. Each bar represents the mean + SEM. (J–O) Recurrent BROMO infusion in VTA effects on CRR. (J) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO (n = 7–9, 5 μg/day; infusion rate 0.1 μL/min). (K) BG concentration during hyperinsulinemic-hypoglycemic clamp, which held BG at 40–50 mg/dL for 90 min. Groups were compared via two-way ANOVA. (L) Ginf. rate during clamp (∗∗∗∗ p < 0.001 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (M) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.05 BROMO vs. SAL). Groups were analyzed via unpaired t test. (N) Relative gene expression of DRD2 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA (∗ p < 0.05 aCSF vs. BROMO). Groups were compared via unpaired t test. (O) Relative gene expression of SLC6A3 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA ( p = 0.21). Groups were compared via unpaired t test. Each bar represents the mean + SEM.
Gene Exp Drd2 Hs00241436 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drd2/Gene+Exp%2E+DRD2%2C+Hs00241436_m1/pm41977324-170-29-15
Average 99 stars, based on 1 article reviews
gene exp drd2 hs00241436 m1 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

96
Thermo Fisher snp drd2 c 7486676 10
Sympathoadrenal response and dopaminergic action with agonist bromocriptine (A–C) Recurrent BROMO administration in i.c.v. reduced food intake and BG response. (A) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) for 3 days into i.c.v. (B) BG on day 4 following singular injection of INS (15 U/kg NPH) Groups were compared via two-way ANOVA. (C) Cumulative food intake after INS injection (∗ p < 0.005 RBROMO i.c.v. vs. RCSF i.c.v. + INS). Groups were compared via unpaired t test. Each bar represents the mean + SEM. (D–H) Recurrent BROMO administration in i.c.v. and effects on CRR. (D) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) into i.c.v.. (E) BG during hyperinsulinemic-hypoglycemic clamp where BG is held at 40–45 mg/dL for 90 min. Groups were compared via two-way ANOVA. (F) Ginf. Rate during clamp (∗∗∗∗ p < 0.0001 vs. RBROMO). Groups were compared via unpaired t test. (G) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (H) Peak glucagon concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. Each bar represents the mean + SEM. (I) Dopaminergic gene expression in VTA. Relative gene product expression of COMT, DDC, <t>DRD2,</t> SLC6A3 in the ventral tegmental area following 3-day treatment with RS ( n = 6), RH ( n = 7), or RH + MET ( n = 6) (∗ p < 0.04 RS vs. RH + MET; # p < 0.04 RH vs. RH + MET). Groups were compared via one-way ANOVA. Each bar represents the mean + SEM. (J–O) Recurrent BROMO infusion in VTA effects on CRR. (J) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO (n = 7–9, 5 μg/day; infusion rate 0.1 μL/min). (K) BG concentration during hyperinsulinemic-hypoglycemic clamp, which held BG at 40–50 mg/dL for 90 min. Groups were compared via two-way ANOVA. (L) Ginf. rate during clamp (∗∗∗∗ p < 0.001 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (M) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.05 BROMO vs. SAL). Groups were analyzed via unpaired t test. (N) Relative gene expression of DRD2 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA (∗ p < 0.05 aCSF vs. BROMO). Groups were compared via unpaired t test. (O) Relative gene expression of SLC6A3 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA ( p = 0.21). Groups were compared via unpaired t test. Each bar represents the mean + SEM.
Snp Drd2 C 7486676 10, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drd2/SNP+DRD2%2C+C___7486676_10/pmc13105473-204-21--1
Average 96 stars, based on 1 article reviews
snp drd2 c 7486676 10 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

94
Proteintech d2r
Sympathoadrenal response and dopaminergic action with agonist bromocriptine (A–C) Recurrent BROMO administration in i.c.v. reduced food intake and BG response. (A) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) for 3 days into i.c.v. (B) BG on day 4 following singular injection of INS (15 U/kg NPH) Groups were compared via two-way ANOVA. (C) Cumulative food intake after INS injection (∗ p < 0.005 RBROMO i.c.v. vs. RCSF i.c.v. + INS). Groups were compared via unpaired t test. Each bar represents the mean + SEM. (D–H) Recurrent BROMO administration in i.c.v. and effects on CRR. (D) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) into i.c.v.. (E) BG during hyperinsulinemic-hypoglycemic clamp where BG is held at 40–45 mg/dL for 90 min. Groups were compared via two-way ANOVA. (F) Ginf. Rate during clamp (∗∗∗∗ p < 0.0001 vs. RBROMO). Groups were compared via unpaired t test. (G) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (H) Peak glucagon concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. Each bar represents the mean + SEM. (I) Dopaminergic gene expression in VTA. Relative gene product expression of COMT, DDC, <t>DRD2,</t> SLC6A3 in the ventral tegmental area following 3-day treatment with RS ( n = 6), RH ( n = 7), or RH + MET ( n = 6) (∗ p < 0.04 RS vs. RH + MET; # p < 0.04 RH vs. RH + MET). Groups were compared via one-way ANOVA. Each bar represents the mean + SEM. (J–O) Recurrent BROMO infusion in VTA effects on CRR. (J) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO (n = 7–9, 5 μg/day; infusion rate 0.1 μL/min). (K) BG concentration during hyperinsulinemic-hypoglycemic clamp, which held BG at 40–50 mg/dL for 90 min. Groups were compared via two-way ANOVA. (L) Ginf. rate during clamp (∗∗∗∗ p < 0.001 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (M) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.05 BROMO vs. SAL). Groups were analyzed via unpaired t test. (N) Relative gene expression of DRD2 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA (∗ p < 0.05 aCSF vs. BROMO). Groups were compared via unpaired t test. (O) Relative gene expression of SLC6A3 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA ( p = 0.21). Groups were compared via unpaired t test. Each bar represents the mean + SEM.
D2r, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drd2/DRD2+Fusion+Protein/pm41895714-113-56-57
Average 94 stars, based on 1 article reviews
d2r - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

86
Mutant Mouse Resource & Research Center d2cre b6 fvb cg tg drd2 cre er44gsat mmucd
Head-fixed mice learn to perform skilled forelimb movements to obtain a reward (A) Representation of injecting AAV9-hSyn-GRAB DA2h and AAV1-Syn-Flex-NES-jRGECO1a into M1. Coronal sections obtained from D1Cre and <t>D2Cre</t> mice showing expression of GRAB DA2h (green) and jRGECO1a (red) in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 500 μm. Magnification: 20×. See also for the histological map of GRAB DA2h and jRGECO1a expression and fiber tip placements. (B) Representation of the task in which head-fixed mice perform skilled forelimb movements with a joystick to obtain a delayed reward, and a fiber photometry setup for simultaneous recording of DA dynamics and population level Ca 2+ activity in the M1 forelimb area. See also for representative traces of neuronal Ca 2+ and DA signals acquired during training. (C) Increase in the number of rewarded joystick movements in D1Cre mice during training. (D) Movement kinematic parameters obtained from the early and late sessions in D1Cre mice showing that the average movement amplitude and velocity increased between training phases. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (E) Individual movement trajectories of an example D1Cre mouse aligned to the initial joystick position (black dot), and preferred movement direction in the group of D1Cre animals (based on all extracted trajectories). (F) Change in movement similarity in D1Cre mice (based on the average distance between pairwise trajectories). (Left to right) Similarity between the early and late sessions; similarity within the late session. (G–J) Same as (C)–(F) for D2Cre mice. In (C)–(J), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
D2cre B6 Fvb Cg Tg Drd2 Cre Er44gsat Mmucd, supplied by Mutant Mouse Resource & Research Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/drd2/adora2a+b6+cg+cre+fvb+kg139gsat+mmucd+tg/pmc12969090-36-0-3
Average 86 stars, based on 1 article reviews
d2cre b6 fvb cg tg drd2 cre er44gsat mmucd - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


(A, B). Single-cell dose-response curves for (A) Gαs-coupled DRD1 and (B) Gαi-coupled DRD2 in CHO-K1::cAMPinG1 cells transiently expressing HALO-tagged receptors. DRD2 was stimulated in the presence of 10 µM forskolin to elevate the baseline cAMP level. Cells are binned and colored by their measured surface receptor abundance (arbitrary flow-cytometry units; see color bars). Solid lines represent joint fits of the operational model (R 2 = 0.98 for DRD1; R 2 = 0.97 for DRD2) with binding affinity (Kd) locked to established IUPHAR values (fit values and 95% CIs are provided in ). Data represent per-bin medians, with error bars indicating ±1 SEM across independent replicate dates (n = 4 for DRD1, n = 5 for DRD2). The remaining subtypes (DRD3, DRD4, DRD5) are characterized in Fig. S3. (C, D) DRD1 dopamine dose-response under siRNA knockdown of Gαs at (C) 1 nM and (D) 33 nM siGNAS (ΔGs), overlaid on the wild-type Gαs response, binned by surface DRD1 abundance (colors as in A). Solid lines are the shared-parameter operational-model fit in which only the available transducer pool [Gs] varies per condition ; Gαs depletion right-shifts the curves along the dose axis without lowering the maximal response. (E). Schematic of the modified operational model. Ligand binding ([L]) yields a fractional receptor occupancy (ρ). This fraction is multiplied by the measured surface receptor abundance ([R]) to yield a composite signaling drive (D = [R] · [G] · ρ). The drive is processed through a saturable Hill-type transducer function (S) to compute the final integrated cAMP output (y). Full mathematical derivation is provided in the Supplementary Information. (F). Master-curve collapse across receptor abundances. Plotting the normalized transducer output (S) against the composite signaling drive (D) collapses the variable dose-response families onto a single, invariant master curve for each receptor subtype. This confirms that cellular cAMP responses are governed by the combined drive quantity rather than receptor density or ligand concentration independently.

Journal: bioRxiv

Article Title: Adenylyl cyclases combinatorially integrate opposing dopamine receptor signals

doi: 10.64898/2026.07.10.737756

Figure Lengend Snippet: (A, B). Single-cell dose-response curves for (A) Gαs-coupled DRD1 and (B) Gαi-coupled DRD2 in CHO-K1::cAMPinG1 cells transiently expressing HALO-tagged receptors. DRD2 was stimulated in the presence of 10 µM forskolin to elevate the baseline cAMP level. Cells are binned and colored by their measured surface receptor abundance (arbitrary flow-cytometry units; see color bars). Solid lines represent joint fits of the operational model (R 2 = 0.98 for DRD1; R 2 = 0.97 for DRD2) with binding affinity (Kd) locked to established IUPHAR values (fit values and 95% CIs are provided in ). Data represent per-bin medians, with error bars indicating ±1 SEM across independent replicate dates (n = 4 for DRD1, n = 5 for DRD2). The remaining subtypes (DRD3, DRD4, DRD5) are characterized in Fig. S3. (C, D) DRD1 dopamine dose-response under siRNA knockdown of Gαs at (C) 1 nM and (D) 33 nM siGNAS (ΔGs), overlaid on the wild-type Gαs response, binned by surface DRD1 abundance (colors as in A). Solid lines are the shared-parameter operational-model fit in which only the available transducer pool [Gs] varies per condition ; Gαs depletion right-shifts the curves along the dose axis without lowering the maximal response. (E). Schematic of the modified operational model. Ligand binding ([L]) yields a fractional receptor occupancy (ρ). This fraction is multiplied by the measured surface receptor abundance ([R]) to yield a composite signaling drive (D = [R] · [G] · ρ). The drive is processed through a saturable Hill-type transducer function (S) to compute the final integrated cAMP output (y). Full mathematical derivation is provided in the Supplementary Information. (F). Master-curve collapse across receptor abundances. Plotting the normalized transducer output (S) against the composite signaling drive (D) collapses the variable dose-response families onto a single, invariant master curve for each receptor subtype. This confirms that cellular cAMP responses are governed by the combined drive quantity rather than receptor density or ligand concentration independently.

Article Snippet: For experiments involving Gαi-coupled receptors (DRD2, DRD3, DRD4), adenylyl cyclase was activated with 10 μM forskolin (MedChemExpress, HY-15371) 5 minutes post-dopamine treatment.

Techniques: Single Cell, Expressing, Flow Cytometry, Binding Assay, Knockdown, Modification, Ligand Binding Assay, Concentration Assay

(A–C) Single-cell dose-response curves for (A) Gαo-coupled DRD3, (B) Gαi-coupled DRD4, and (C) Gαs-coupled DRD5 in CHO-K1::cAMPinG1 cells transiently expressing HALO-tagged receptors. The Gαi/o-coupled subtypes (DRD3, DRD4) were stimulated in the presence of 10 µM forskolin to elevate the baseline cAMP level; the Gαs-coupled DRD5 was measured from the unstimulated baseline. Cells are binned and colored by their measured surface receptor abundance (arbitrary flow-cytometry units; see color bar). Solid lines represent fits of the operational model with binding affinity (Kd) locked to established IUPHAR values (fit values and 95% CIs are provided in ). Data represent per-bin medians, with error bars indicating ±1 SEM across independent replicate dates (n = 2 for DRD3, n = 3 for DRD4, n = 4 for DRD5). (A) DRD3 produces no dopamine-evoked cAMP response, because its primary transducer Gαo is not endogenously expressed in CHO-K1 ; it therefore serves as a silent control. (B) DRD4 shows shallow, expression-dependent suppression of the forskolin-elevated baseline (R 2 = 0.91), consistent with DRD4’s canonical preference for Gαo over Gαi. (C) DRD5 shows expression-dependent cAMP stimulation (R 2 = 0.97). These subtypes are reported for completeness of the receptor panel and are not used in any quantitative downstream analysis; the identifiability of their fits is examined in .

Journal: bioRxiv

Article Title: Adenylyl cyclases combinatorially integrate opposing dopamine receptor signals

doi: 10.64898/2026.07.10.737756

Figure Lengend Snippet: (A–C) Single-cell dose-response curves for (A) Gαo-coupled DRD3, (B) Gαi-coupled DRD4, and (C) Gαs-coupled DRD5 in CHO-K1::cAMPinG1 cells transiently expressing HALO-tagged receptors. The Gαi/o-coupled subtypes (DRD3, DRD4) were stimulated in the presence of 10 µM forskolin to elevate the baseline cAMP level; the Gαs-coupled DRD5 was measured from the unstimulated baseline. Cells are binned and colored by their measured surface receptor abundance (arbitrary flow-cytometry units; see color bar). Solid lines represent fits of the operational model with binding affinity (Kd) locked to established IUPHAR values (fit values and 95% CIs are provided in ). Data represent per-bin medians, with error bars indicating ±1 SEM across independent replicate dates (n = 2 for DRD3, n = 3 for DRD4, n = 4 for DRD5). (A) DRD3 produces no dopamine-evoked cAMP response, because its primary transducer Gαo is not endogenously expressed in CHO-K1 ; it therefore serves as a silent control. (B) DRD4 shows shallow, expression-dependent suppression of the forskolin-elevated baseline (R 2 = 0.91), consistent with DRD4’s canonical preference for Gαo over Gαi. (C) DRD5 shows expression-dependent cAMP stimulation (R 2 = 0.97). These subtypes are reported for completeness of the receptor panel and are not used in any quantitative downstream analysis; the identifiability of their fits is examined in .

Article Snippet: For experiments involving Gαi-coupled receptors (DRD2, DRD3, DRD4), adenylyl cyclase was activated with 10 μM forskolin (MedChemExpress, HY-15371) 5 minutes post-dopamine treatment.

Techniques: Single Cell, Expressing, Flow Cytometry, Binding Assay, Control

(A) Per-receptor scatter of dopamine binding measurements before and after the stringent curation that produced . Each colored point (orange = Gαs-coupled, blue = Gαi-coupled) is one of the 24 measurements retained in the main figure; each light-grey point is a measurement excluded by one or more curation criteria (see Methods and panel B of this figure). All rows that map to one of the five dopamine receptors are included, with descriptions like “D2L”, “D2A”, and “D2long” mapped to DRD2 (long isoform) by an extended description-matching rule applied in this SI figure but not in the main-text curation, in order to expose the full per-receptor scatter that the database contains. n (kept/total): DRD1 = 6/39, DRD5 = 1/2, DRD2 = 5/116, DRD3 = 10/50, DRD4 = 2/21. Solid colored bars, stringent median (matches ); dashed black ticks, unfiltered median across all rows shown. The two medians lie within 0.1 log unit (≈25%) of each other for every receptor that has more than one entry, indicating that the stringent filter narrows the database but does not systematically bias the central tendency. (B) Counts of GtoPdb rows excluded by each curation criterion. Each row is assigned to the first applicable category in the order: functional assay (Assay Type = “F” in GtoPdb; signaling readouts such as cAMP, β-arrestin recruitment, or [ S]GTPγS binding rather than direct ligand binding), species not specified (assay description does not explicitly state the species), non-human species (description names rat, mouse, bovine, dog, or porcine receptor), other / multiple (combinations of the above or unparseable values, value reported as a range, or “unknown origin” phrase in description), unrecognized assay type (Assay Type column does not contain the standard B/F values).

Journal: bioRxiv

Article Title: Adenylyl cyclases combinatorially integrate opposing dopamine receptor signals

doi: 10.64898/2026.07.10.737756

Figure Lengend Snippet: (A) Per-receptor scatter of dopamine binding measurements before and after the stringent curation that produced . Each colored point (orange = Gαs-coupled, blue = Gαi-coupled) is one of the 24 measurements retained in the main figure; each light-grey point is a measurement excluded by one or more curation criteria (see Methods and panel B of this figure). All rows that map to one of the five dopamine receptors are included, with descriptions like “D2L”, “D2A”, and “D2long” mapped to DRD2 (long isoform) by an extended description-matching rule applied in this SI figure but not in the main-text curation, in order to expose the full per-receptor scatter that the database contains. n (kept/total): DRD1 = 6/39, DRD5 = 1/2, DRD2 = 5/116, DRD3 = 10/50, DRD4 = 2/21. Solid colored bars, stringent median (matches ); dashed black ticks, unfiltered median across all rows shown. The two medians lie within 0.1 log unit (≈25%) of each other for every receptor that has more than one entry, indicating that the stringent filter narrows the database but does not systematically bias the central tendency. (B) Counts of GtoPdb rows excluded by each curation criterion. Each row is assigned to the first applicable category in the order: functional assay (Assay Type = “F” in GtoPdb; signaling readouts such as cAMP, β-arrestin recruitment, or [ S]GTPγS binding rather than direct ligand binding), species not specified (assay description does not explicitly state the species), non-human species (description names rat, mouse, bovine, dog, or porcine receptor), other / multiple (combinations of the above or unparseable values, value reported as a range, or “unknown origin” phrase in description), unrecognized assay type (Assay Type column does not contain the standard B/F values).

Article Snippet: For experiments involving Gαi-coupled receptors (DRD2, DRD3, DRD4), adenylyl cyclase was activated with 10 μM forskolin (MedChemExpress, HY-15371) 5 minutes post-dopamine treatment.

Techniques: Binding Assay, Produced, Functional Assay, Ligand Binding Assay

Sympathoadrenal response and dopaminergic action with agonist bromocriptine (A–C) Recurrent BROMO administration in i.c.v. reduced food intake and BG response. (A) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) for 3 days into i.c.v. (B) BG on day 4 following singular injection of INS (15 U/kg NPH) Groups were compared via two-way ANOVA. (C) Cumulative food intake after INS injection (∗ p < 0.005 RBROMO i.c.v. vs. RCSF i.c.v. + INS). Groups were compared via unpaired t test. Each bar represents the mean + SEM. (D–H) Recurrent BROMO administration in i.c.v. and effects on CRR. (D) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) into i.c.v.. (E) BG during hyperinsulinemic-hypoglycemic clamp where BG is held at 40–45 mg/dL for 90 min. Groups were compared via two-way ANOVA. (F) Ginf. Rate during clamp (∗∗∗∗ p < 0.0001 vs. RBROMO). Groups were compared via unpaired t test. (G) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (H) Peak glucagon concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. Each bar represents the mean + SEM. (I) Dopaminergic gene expression in VTA. Relative gene product expression of COMT, DDC, DRD2, SLC6A3 in the ventral tegmental area following 3-day treatment with RS ( n = 6), RH ( n = 7), or RH + MET ( n = 6) (∗ p < 0.04 RS vs. RH + MET; # p < 0.04 RH vs. RH + MET). Groups were compared via one-way ANOVA. Each bar represents the mean + SEM. (J–O) Recurrent BROMO infusion in VTA effects on CRR. (J) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO (n = 7–9, 5 μg/day; infusion rate 0.1 μL/min). (K) BG concentration during hyperinsulinemic-hypoglycemic clamp, which held BG at 40–50 mg/dL for 90 min. Groups were compared via two-way ANOVA. (L) Ginf. rate during clamp (∗∗∗∗ p < 0.001 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (M) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.05 BROMO vs. SAL). Groups were analyzed via unpaired t test. (N) Relative gene expression of DRD2 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA (∗ p < 0.05 aCSF vs. BROMO). Groups were compared via unpaired t test. (O) Relative gene expression of SLC6A3 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA ( p = 0.21). Groups were compared via unpaired t test. Each bar represents the mean + SEM.

Journal: Cell Reports Medicine

Article Title: Role of dopamine in the development of impaired counterregulation and impaired awareness of hypoglycemia

doi: 10.1016/j.xcrm.2026.102710

Figure Lengend Snippet: Sympathoadrenal response and dopaminergic action with agonist bromocriptine (A–C) Recurrent BROMO administration in i.c.v. reduced food intake and BG response. (A) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) for 3 days into i.c.v. (B) BG on day 4 following singular injection of INS (15 U/kg NPH) Groups were compared via two-way ANOVA. (C) Cumulative food intake after INS injection (∗ p < 0.005 RBROMO i.c.v. vs. RCSF i.c.v. + INS). Groups were compared via unpaired t test. Each bar represents the mean + SEM. (D–H) Recurrent BROMO administration in i.c.v. and effects on CRR. (D) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO ( n = 7, 2 μg) into i.c.v.. (E) BG during hyperinsulinemic-hypoglycemic clamp where BG is held at 40–45 mg/dL for 90 min. Groups were compared via two-way ANOVA. (F) Ginf. Rate during clamp (∗∗∗∗ p < 0.0001 vs. RBROMO). Groups were compared via unpaired t test. (G) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (H) Peak glucagon concentrations at basal and hypoglycemia (∗ p < 0.005 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. Each bar represents the mean + SEM. (I) Dopaminergic gene expression in VTA. Relative gene product expression of COMT, DDC, DRD2, SLC6A3 in the ventral tegmental area following 3-day treatment with RS ( n = 6), RH ( n = 7), or RH + MET ( n = 6) (∗ p < 0.04 RS vs. RH + MET; # p < 0.04 RH vs. RH + MET). Groups were compared via one-way ANOVA. Each bar represents the mean + SEM. (J–O) Recurrent BROMO infusion in VTA effects on CRR. (J) Schematic diagram of recurrent aCSF ( n = 7) or recurrent BROMO (n = 7–9, 5 μg/day; infusion rate 0.1 μL/min). (K) BG concentration during hyperinsulinemic-hypoglycemic clamp, which held BG at 40–50 mg/dL for 90 min. Groups were compared via two-way ANOVA. (L) Ginf. rate during clamp (∗∗∗∗ p < 0.001 RCSF vs. RBROMO). Groups were compared via two-way ANOVA. (M) Peak epinephrine concentrations at basal and hypoglycemia (∗ p < 0.05 BROMO vs. SAL). Groups were analyzed via unpaired t test. (N) Relative gene expression of DRD2 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA (∗ p < 0.05 aCSF vs. BROMO). Groups were compared via unpaired t test. (O) Relative gene expression of SLC6A3 in the ventral tegmental area following a 3-day treatment with either aCSF or BROMO directly into the VTA ( p = 0.21). Groups were compared via unpaired t test. Each bar represents the mean + SEM.

Article Snippet: In brief, total RNA was extracted and purified from brain regions using miRNeasy Mini Kit (Qiagen, CA) which was reverse transcribed and then amplified by real-time PCR using Taqman gene assays (Thermo Fisher) for dopamine receptor D2 ( Drd2 ; assay ID: Rn00561126_m1), dopamine transporter or solute carrier family 6, member 3 ( Dat or Slc6a3 ; assay ID: Rn00562224_m1), dopa decarboxylase ( Ddc : assay ID: Rn01401189_m1), catechol- O -methyltransferase ( Comt ; assay ID: Rn00561037_m1) and the housekeeping gene beta-actin ( Actb ; assay ID: Rn00667869_m1).

Techniques: Injection, Gene Expression, Expressing, Concentration Assay

Head-fixed mice learn to perform skilled forelimb movements to obtain a reward (A) Representation of injecting AAV9-hSyn-GRAB DA2h and AAV1-Syn-Flex-NES-jRGECO1a into M1. Coronal sections obtained from D1Cre and D2Cre mice showing expression of GRAB DA2h (green) and jRGECO1a (red) in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 500 μm. Magnification: 20×. See also for the histological map of GRAB DA2h and jRGECO1a expression and fiber tip placements. (B) Representation of the task in which head-fixed mice perform skilled forelimb movements with a joystick to obtain a delayed reward, and a fiber photometry setup for simultaneous recording of DA dynamics and population level Ca 2+ activity in the M1 forelimb area. See also for representative traces of neuronal Ca 2+ and DA signals acquired during training. (C) Increase in the number of rewarded joystick movements in D1Cre mice during training. (D) Movement kinematic parameters obtained from the early and late sessions in D1Cre mice showing that the average movement amplitude and velocity increased between training phases. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (E) Individual movement trajectories of an example D1Cre mouse aligned to the initial joystick position (black dot), and preferred movement direction in the group of D1Cre animals (based on all extracted trajectories). (F) Change in movement similarity in D1Cre mice (based on the average distance between pairwise trajectories). (Left to right) Similarity between the early and late sessions; similarity within the late session. (G–J) Same as (C)–(F) for D2Cre mice. In (C)–(J), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

Journal: iScience

Article Title: The role of dopamine-sensitive motor cortical circuits in the development and execution of skilled forelimb movements

doi: 10.1016/j.isci.2026.114983

Figure Lengend Snippet: Head-fixed mice learn to perform skilled forelimb movements to obtain a reward (A) Representation of injecting AAV9-hSyn-GRAB DA2h and AAV1-Syn-Flex-NES-jRGECO1a into M1. Coronal sections obtained from D1Cre and D2Cre mice showing expression of GRAB DA2h (green) and jRGECO1a (red) in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 500 μm. Magnification: 20×. See also for the histological map of GRAB DA2h and jRGECO1a expression and fiber tip placements. (B) Representation of the task in which head-fixed mice perform skilled forelimb movements with a joystick to obtain a delayed reward, and a fiber photometry setup for simultaneous recording of DA dynamics and population level Ca 2+ activity in the M1 forelimb area. See also for representative traces of neuronal Ca 2+ and DA signals acquired during training. (C) Increase in the number of rewarded joystick movements in D1Cre mice during training. (D) Movement kinematic parameters obtained from the early and late sessions in D1Cre mice showing that the average movement amplitude and velocity increased between training phases. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (E) Individual movement trajectories of an example D1Cre mouse aligned to the initial joystick position (black dot), and preferred movement direction in the group of D1Cre animals (based on all extracted trajectories). (F) Change in movement similarity in D1Cre mice (based on the average distance between pairwise trajectories). (Left to right) Similarity between the early and late sessions; similarity within the late session. (G–J) Same as (C)–(F) for D2Cre mice. In (C)–(J), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

Article Snippet: D2Cre: B6.FVB(Cg)-Tg(Drd2-cre)ER44Gsat/Mmucd , MMRRC: UCD , RRID: MMRRC_032108-UCD.

Techniques: Expressing, Activity Assay

DA dynamics in the M1 encode execution of skilled forelimb movement and reward consumption (A) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the baseline (BL) and between-session comparisons of movement- and reward-related periods (early vs. late). (B) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the BL and between-session comparisons of movement- and reward-related periods (early vs. late). (C) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the BL and between-session comparisons of movement- and reward-related periods (early vs. late). (D–F) Same as (A)–(C) for D2Cre mice. In (A)–(F), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Repeated-measure one-way ANOVA; multiple comparisons: BL mean vs. every other mean, movement (0–1 s) mean vs. reward (1–2 s) mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; or paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice and cross-correlations between DA and Ca 2+ signals.

Journal: iScience

Article Title: The role of dopamine-sensitive motor cortical circuits in the development and execution of skilled forelimb movements

doi: 10.1016/j.isci.2026.114983

Figure Lengend Snippet: DA dynamics in the M1 encode execution of skilled forelimb movement and reward consumption (A) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the baseline (BL) and between-session comparisons of movement- and reward-related periods (early vs. late). (B) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the BL and between-session comparisons of movement- and reward-related periods (early vs. late). (C) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (early or late) comparisons with respect to the BL and between-session comparisons of movement- and reward-related periods (early vs. late). (D–F) Same as (A)–(C) for D2Cre mice. In (A)–(F), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Repeated-measure one-way ANOVA; multiple comparisons: BL mean vs. every other mean, movement (0–1 s) mean vs. reward (1–2 s) mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; or paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice and cross-correlations between DA and Ca 2+ signals.

Article Snippet: D2Cre: B6.FVB(Cg)-Tg(Drd2-cre)ER44Gsat/Mmucd , MMRRC: UCD , RRID: MMRRC_032108-UCD.

Techniques:

The neural response in the M1 reflects the movement vigor (A and B) Movement kinematic parameters obtained from the low- and high-amplitude trials during regular threshold session in D1Cre and D2Cre mice showing the difference in response vigor. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (C) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (D) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (E) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low and high amplitude trials (bottom). (F–H) Same as (C)–(E) for D2Cre mice. In (A)–(H), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice.

Journal: iScience

Article Title: The role of dopamine-sensitive motor cortical circuits in the development and execution of skilled forelimb movements

doi: 10.1016/j.isci.2026.114983

Figure Lengend Snippet: The neural response in the M1 reflects the movement vigor (A and B) Movement kinematic parameters obtained from the low- and high-amplitude trials during regular threshold session in D1Cre and D2Cre mice showing the difference in response vigor. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (C) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (D) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (E) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low and high amplitude trials (bottom). (F–H) Same as (C)–(E) for D2Cre mice. In (A)–(H), data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice.

Article Snippet: D2Cre: B6.FVB(Cg)-Tg(Drd2-cre)ER44Gsat/Mmucd , MMRRC: UCD , RRID: MMRRC_032108-UCD.

Techniques:

The neural response in the M1 reflects the movement vigor during the increased threshold session (A and B) Movement kinematic parameters obtained from the low- and high-amplitude trials during the increased threshold session in D1Cre and D2Cre mice. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (C) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (D) Peri-event plots of the average normalized Ca 2+ signaling D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (E) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (F–H) Same as (C)–(E) for D2Cre mice. In (A)–(H) Data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-), and 12 D2Cre (10 Cre+ and 2 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice.

Journal: iScience

Article Title: The role of dopamine-sensitive motor cortical circuits in the development and execution of skilled forelimb movements

doi: 10.1016/j.isci.2026.114983

Figure Lengend Snippet: The neural response in the M1 reflects the movement vigor during the increased threshold session (A and B) Movement kinematic parameters obtained from the low- and high-amplitude trials during the increased threshold session in D1Cre and D2Cre mice. (Left to right) Distribution of movement amplitudes, movement amplitude, and joystick velocity at the time of threshold crossing. (C) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (D) Peri-event plots of the average normalized Ca 2+ signaling D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (E) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and comparisons of movement- and reward-related periods (analyzed at 1-s intervals) between low- and high-amplitude trials (bottom). (F–H) Same as (C)–(E) for D2Cre mice. In (A)–(H) Data were obtained from 14 D1Cre (10 Cre+ and 4 Cre-), and 12 D2Cre (10 Cre+ and 2 Cre-) animals. Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05. Dashed lines indicate joystick movement (threshold crossing) and reward delivery. See also for comparisons between D1Cre and D2Cre mice.

Article Snippet: D2Cre: B6.FVB(Cg)-Tg(Drd2-cre)ER44Gsat/Mmucd , MMRRC: UCD , RRID: MMRRC_032108-UCD.

Techniques:

DA in the M1 signals actual reward availability during skilled performance (A) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the baseline (BL). (B) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the BL. (C) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the BL. (D–F) Same as (A)–(C) for D2Cre mice. In (A)–(F), data for “delayed reward” analysis were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals and for “omission” analysis from 9 D1Cre (7 Cre+ and 2 Cre-) and 8 D2Cre (8 Cre+) animals. Data are represented as mean ± SEM. Repeated-measure one-way ANOVA; multiple comparisons: BL mean vs. every other mean, movement (0–1 s) mean vs. expected reward (1–2 s) mean, expected reward (1–2 s) mean vs. actual reward (3–4 s) mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05 See also for comparisons between D1Cre and D2Cre mice.

Journal: iScience

Article Title: The role of dopamine-sensitive motor cortical circuits in the development and execution of skilled forelimb movements

doi: 10.1016/j.isci.2026.114983

Figure Lengend Snippet: DA in the M1 signals actual reward availability during skilled performance (A) Peri-event plots of the average normalized DA signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the baseline (BL). (B) Peri-event plots of the average normalized Ca 2+ signal in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the BL. (C) Peri-event plots of the average lick rate (licks/s) in D1Cre mice aligned to threshold cross (top) and binned data analyzed at 1-s intervals (bottom). (Left to right) Data are presented as within-session (delay or omission) comparisons with respect to the BL. (D–F) Same as (A)–(C) for D2Cre mice. In (A)–(F), data for “delayed reward” analysis were obtained from 14 D1Cre (10 Cre+ and 4 Cre-) and 13 D2Cre (10 Cre+ and 3 Cre-) animals and for “omission” analysis from 9 D1Cre (7 Cre+ and 2 Cre-) and 8 D2Cre (8 Cre+) animals. Data are represented as mean ± SEM. Repeated-measure one-way ANOVA; multiple comparisons: BL mean vs. every other mean, movement (0–1 s) mean vs. expected reward (1–2 s) mean, expected reward (1–2 s) mean vs. actual reward (3–4 s) mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05 See also for comparisons between D1Cre and D2Cre mice.

Article Snippet: D2Cre: B6.FVB(Cg)-Tg(Drd2-cre)ER44Gsat/Mmucd , MMRRC: UCD , RRID: MMRRC_032108-UCD.

Techniques:

A subset of D1+ and D2+ neurons of the M1 contacts long-range targets (A) Representation of the four major areas of rAAV2-Retro-EYFP and Fluoro-Green injections: primary motor cortex (M1), dorsolateral striatum (DLS), thalamus (Thal), and pontine nucleus (PN). See also for representative histology of the injection sites. (B and C) Coronal sections obtained from D1-tdTomato and D2Cre::Ai14 (tdTomato) mice showing laminar distribution of tdTomato (red) expressing D1+ or D2+ neurons and EYFP or FGr (green) expressing retrogradely labeled projection neurons in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 50 μm. See also for analysis of laminar distributions. (D) Cell density of D1+ neurons plotted as a function of distance from pia (where pia = 0 and white matter = 1; therefore, <0.5 indicates cells clustered in the upper layers, while >0.5 indicates cells clustered in the deep layers). (E) Colocalization of D1+ neurons with different populations of projection neurons. Percentage of D1+ neurons indicates colabeled cells across all layers that are also EYFP+ (% [D1+ EYFP+] / D1+) or FGr+ (% [D1+ FGr+] / D1+). Percentage of EYFP+ neurons indicates cells that are also D1+ (% [D1+ EYFP+] / EYFP+), and percentage of FGr+ neurons indicates cells that are D1+ (% [D1+ FGr+] / FGr+). (F) Comparison of labeling specificity of rAAV2-retro and FGr tracers measured by the number of cells labeled by each tracer. (G–I) Same as (D)–(F) for D2Cre mice. In (D)–(I), data were obtained from 21 D1-tdTomato and 19 D2Cre::Ai14 animals (2–3 mice per injection site, 4 slices per animal, slices were collected from −0.10 mm posterior to 1.00 mm anterior to the bregma). Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001. Two-way ANOVA; multiple comparisons: EYFP mean vs. FGr mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01. (B–I) cM1 (primary motor cortex injection, M1 forelimb area contralateral to the injection site); cDLS (DLS injection, M1 forelimb area contralateral to the injection site); iDLS (dorsolateral striatum injection, M1 forelimb area ipsilateral to the injection site); iThal (thalmus injection, M1 forelimb area ipsilateral to the injection site); iPN (pontine nucleus injection, M1 forelimb area ipsilateral to the injection site).

Journal: iScience

Article Title: The role of dopamine-sensitive motor cortical circuits in the development and execution of skilled forelimb movements

doi: 10.1016/j.isci.2026.114983

Figure Lengend Snippet: A subset of D1+ and D2+ neurons of the M1 contacts long-range targets (A) Representation of the four major areas of rAAV2-Retro-EYFP and Fluoro-Green injections: primary motor cortex (M1), dorsolateral striatum (DLS), thalamus (Thal), and pontine nucleus (PN). See also for representative histology of the injection sites. (B and C) Coronal sections obtained from D1-tdTomato and D2Cre::Ai14 (tdTomato) mice showing laminar distribution of tdTomato (red) expressing D1+ or D2+ neurons and EYFP or FGr (green) expressing retrogradely labeled projection neurons in the M1 forelimb area (brain slices are 0.5 mm anterior to the bregma). Scale bars, 50 μm. See also for analysis of laminar distributions. (D) Cell density of D1+ neurons plotted as a function of distance from pia (where pia = 0 and white matter = 1; therefore, <0.5 indicates cells clustered in the upper layers, while >0.5 indicates cells clustered in the deep layers). (E) Colocalization of D1+ neurons with different populations of projection neurons. Percentage of D1+ neurons indicates colabeled cells across all layers that are also EYFP+ (% [D1+ EYFP+] / D1+) or FGr+ (% [D1+ FGr+] / D1+). Percentage of EYFP+ neurons indicates cells that are also D1+ (% [D1+ EYFP+] / EYFP+), and percentage of FGr+ neurons indicates cells that are D1+ (% [D1+ FGr+] / FGr+). (F) Comparison of labeling specificity of rAAV2-retro and FGr tracers measured by the number of cells labeled by each tracer. (G–I) Same as (D)–(F) for D2Cre mice. In (D)–(I), data were obtained from 21 D1-tdTomato and 19 D2Cre::Ai14 animals (2–3 mice per injection site, 4 slices per animal, slices were collected from −0.10 mm posterior to 1.00 mm anterior to the bregma). Data are represented as mean ± SEM. Paired t test; ∗∗∗ p < 0.001. Two-way ANOVA; multiple comparisons: EYFP mean vs. FGr mean; Bonferroni’s post hoc test; ∗∗∗ p < 0.001, ∗∗ p < 0.01. (B–I) cM1 (primary motor cortex injection, M1 forelimb area contralateral to the injection site); cDLS (DLS injection, M1 forelimb area contralateral to the injection site); iDLS (dorsolateral striatum injection, M1 forelimb area ipsilateral to the injection site); iThal (thalmus injection, M1 forelimb area ipsilateral to the injection site); iPN (pontine nucleus injection, M1 forelimb area ipsilateral to the injection site).

Article Snippet: D2Cre: B6.FVB(Cg)-Tg(Drd2-cre)ER44Gsat/Mmucd , MMRRC: UCD , RRID: MMRRC_032108-UCD.

Techniques: Injection, Expressing, Labeling, Comparison